1. Slamon, D.J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
2. Cohen, J.A. et al. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene 4, 81–88 (1989).
3. Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A. & Greene, M.I. Development of monoclonal antibodies reactive with the product of the neu oncogene. Symp. Fund. Cancer Res. 38, 277–289 (1986).
4. Drebin, J.A., Link, V.C. & Greene, M.I. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene 2, 387–394 (1988).
5. Baselga, J., Norton, L., Albanell, J., Kim, Y.M. & Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825–2831 (1998).